Literature DB >> 17475848

Sensitization to TLR7 agonist in IFN-beta-preactivated dendritic cells.

Martina Severa1, Maria Elena Remoli, Elena Giacomini, Viviana Annibali, Valerie Gafa, Roberto Lande, Mark Tomai, Marco Salvetti, Eliana M Coccia.   

Abstract

TLRs interact with a growing list of pathogen-derived products and these interactions drive the activation of innate and adaptive immune responses. Dendritic cells (DC) play a key role in these events expressing a heterogeneous repertoire of TLRs. We have previously demonstrated the production of type I IFNs in DC following bacterial infections and TLR triggering. In this study, we sought to characterize the transcriptome specifically induced in human DC by IFN-beta production stimulated upon LPS treatment. To this aim, by using cDNA microarrays, we compared the transcriptome of DC following LPS treatment in the absence or presence of neutralizing anti-type I IFN Abs. Interestingly, we found that the expression of TLR7 was induced during LPS-induced maturation of DC in a type I IFN-dependent manner. The induction of TLR7 in maturing DC was mainly a consequence of the transcriptional activity of IRF-1, whose binding site was located within TLR7 promoter. Moreover, we also demonstrated that "priming" of immature DC, that usually express TLR8 but not TLR7, with exogenous IFN-beta induced a functionally active TLR7. In fact, treatment with the TLR7-specific ligand 3M-001 up-regulated the expression of CD83, CD86, and CD38 in IFN-beta-primed DC but not in immature DC. Therefore, a robust enhancement in proinflammatory as well as regulatory cytokines was observed. These data suggest that TLR4-mediated type I IFN release activates specific transcription programs in DC amplifying the expression of pathogen sensors to correctly and combinatorially respond to a bacterial as well as viral infection.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17475848     DOI: 10.4049/jimmunol.178.10.6208

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  17 in total

Review 1.  The response of human dendritic cells to co-ligation of pattern-recognition receptors.

Authors:  Tanja Dzopalic; Ivan Rajkovic; Ana Dragicevic; Miodrag Colic
Journal:  Immunol Res       Date:  2012-04       Impact factor: 2.829

2.  Assessing the immunopotency of Toll-like receptor agonists in an in vitro tissue-engineered immunological model.

Authors:  Yifan Ma; Louis Poisson; Guzman Sanchez-Schmitz; Santosh Pawar; Chunfeng Qu; Gwendalyn J Randolph; William L Warren; Eric M Mishkin; Russell G Higbee
Journal:  Immunology       Date:  2010-03-17       Impact factor: 7.397

3.  Transcriptional regulation of Tlr11 gene expression in epithelial cells.

Authors:  Zhenyu Cai; Zhongcheng Shi; Amir Sanchez; Tingting Zhang; Mingyao Liu; Jianghua Yang; Fen Wang; Dekai Zhang
Journal:  J Biol Chem       Date:  2009-10-02       Impact factor: 5.157

4.  Ligation of TLR7 by rheumatoid arthritis synovial fluid single strand RNA induces transcription of TNFα in monocytes.

Authors:  Nathan D Chamberlain; Seung-jae Kim; Olga M Vila; Michael V Volin; Suncica Volkov; Richard M Pope; Shiva Arami; Arthur M Mandelin; Shiva Shahrara
Journal:  Ann Rheum Dis       Date:  2012-06-23       Impact factor: 19.103

5.  Combination of TLR8 and TLR4 agonists reduces the degrading effects of nicotine on DC-NK mediated effector T cell generation.

Authors:  Mahyar Nouri-Shirazi; Saba Tamjidi; Erika Nourishirazi; Elisabeth Guinet
Journal:  Int Immunopharmacol       Date:  2018-05-24       Impact factor: 4.932

Review 6.  Monocyte-derived DC maturation strategies and related pathways: a transcriptional view.

Authors:  Luciano Castiello; Marianna Sabatino; Ping Jin; Carol Clayberger; Francesco M Marincola; Alan M Krensky; David F Stroncek
Journal:  Cancer Immunol Immunother       Date:  2011-01-22       Impact factor: 6.968

7.  C/EBP{delta} and STAT-1 are required for TLR8 transcriptional activity.

Authors:  Claudia Zannetti; François Bonnay; Fumihiko Takeshita; Peggy Parroche; Christine Ménétrier-Caux; Massimo Tommasino; Uzma A Hasan
Journal:  J Biol Chem       Date:  2010-09-09       Impact factor: 5.157

Review 8.  Type I interferon in rheumatic diseases.

Authors:  Theresa L Wampler Muskardin; Timothy B Niewold
Journal:  Nat Rev Rheumatol       Date:  2018-03-21       Impact factor: 20.543

9.  Nuclear factor kappaB (NF-kappaB) activation primes cells to a pro-inflammatory polarized response to a Toll-like receptor 7 (TLR7) agonist.

Authors:  Jongdae Lee; Masaaki Hayashi; Jeng-Fan Lo; Colleen Fearns; Wen-Ming Chu; Yunping Luo; Rong Xiang; Tsung-Hsien Chuang
Journal:  Biochem J       Date:  2009-06-26       Impact factor: 3.857

10.  TLR8 combined withTLR3 or TLR4 agonists enhances DC-NK driven effector Tc1 cells.

Authors:  Mahyar Nouri-Shirazi; Saba Tamjidi; Erika Nourishirazi; Elisabeth Guinet
Journal:  Immunol Lett       Date:  2017-12-01       Impact factor: 3.685

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.